4:04 PM ET
8-K
Deal Termination
Prothena Corp Public Ltd Deal Termination with Bristol Myers Squibb
Bristol Myers Squibb (BMS) has terminated its exclusive global license agreement for PRX019 with Prothena following an internal strategic review. As a result of the termination, effective January 28, 2027, Prothena is no longer eligible to receive up to $617.5 million in potential development, regulatory, and sales milestones. BMS will continue to develop moponetug (PRX005) under a separate ongoing collaboration agreement.
- Counterparty
- Bristol Myers Squibb